Companies › Puma Biotechnology
1 active drug program in 5 registered trials: 4 Phase 2, 1 Phase 1; Oncology; next expected readout Oct 2027.
Open in Phaseline: competitors, likelihood bands and readouts Company report
| Drug | Target | Highest phase | Conditions | Next expected readout |
|---|---|---|---|---|
| Alisertib Serine/threonine-protein kinase Aurora-A inhibitor | AURKA | Phase 2 | Small Cell Lung Cancer; Hormone Receptor Positive HER-2 Negative Breast Cancer; Small Cell Lung Cancer ( SCLC ); Malignant Rhabdoid Tumor … | Oct 2027 |
| Registry id | Drug | Phase | Conditions | Area | Expected readout |
|---|---|---|---|---|---|
| NCT01695941 | Alisertib | Phase 1 | Recurrent B-Cell Non-Hodgkin Lymphoma | Oncology | Mar 2027 |
| NCT02114229 | Alisertib | Phase 2 | Malignant Rhabdoid Tumor | Oncology | Sep 2027 |
| NCT06095505 | Alisertib | Phase 2 | Small Cell Lung Cancer | Oncology | Oct 2027 |
| NCT06369285 | Alisertib | Phase 2 | Hormone Receptor Positive HER-2 Negative Breast Cancer | Oncology | Dec 2027 |
| NCT07465757 | Alisertib | Phase 2 | Small Cell Lung Cancer ( SCLC ) | Oncology | Mar 2028 |
Cash and short-term investments of $101m on 2026-09-30; operating cash flow positive
Press releases filed as 8-K in the last year:
Held by 1 of the 39 life-science funds Phaseline follows through their 13F filings. Who holds what.
C4 Therapeutics Compass Therapeutics Shanghai Guangsheng Biopharmaceutical VIVUS Panbela Therapeutics
Pipelines of the same shape: areas, drug types, target families, stage and cash runway.
Programs group the company's trials by drug; the target and mechanism come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood, shown as a band with its track record, is in the app.